Skip to content

Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury

Cranial Nerve Noninvasive Neuromodulation Using the PoNS for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02158494
Enrollment
44
Registered
2014-06-06
Start date
2014-05-31
Completion date
2017-10-31
Last updated
2019-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Traumatic

Keywords

Cranial Nerve Noninvasive Neuromodulation, Portable Neuromodulation Stimulator (PoNS), Balance and Gait Training, Breathing Awareness Training

Brief summary

The investigators hypothesis is that electrical stimulation to the tongue that directly stimulates two cranial nerve nuclei (Trigeminal and Facial Nerve Nuclei), will excite neural impulses to the brainstem and cerebellum. The investigators call this cranial nerve non-invasive neuromodulation (CN-NINM). The activation of these structures induces neuroplasticity when combined with specific physical, cognitive and/or mental exercises, promoting recovery of selected functional damage such as problems with balance or walking. 44 subjects will be recruited for 2 weeks of intensive In-Lab Balance and Gait Training followed by 12 weeks of intensive Home Training with weekly In-Lab check sessions. Half of the subjects will use CN-NINM in conjunction with the exercise. Half of the subjects will use very low level stimulation in conjunction with the exercise, and will serve as a control group.

Detailed description

* Based on the results of the investigators pilot study in moderate traumatic brain injury (M-TBI), the investigators will conduct a randomized, controlled study of cranial nerve non-invasive neuromodulation (CN-NINM) in individuals with chronic symptoms of mild to moderate traumatic brain injury (mTBI), post-concussive sequelae, (PCS) and post-traumatic stress (PTS). * The study will involve training of both balance and gait, with assessments using standardized and relevant metrics to monitor changes in these indications, as well as cognitive function, sleep, headache, anxiety, mood, and eye-movement control. * The training regimen involves using a neurostimulation intervention that addresses primary and secondary symptoms associated with mTBI, PCS, and PTS. * This randomized double blind controlled study will enroll a total of 44 subjects (M & F) in 2 equal subgroups: 22 with an Active PoNS™, and 22 with a Control (non-zero, minimally perceivable stimulation) device. * Subjects will participate in a 3-phase intervention beginning with a 2-week in-lab training program (ITP) (2 in-lab training sessions and 1 home training session daily), followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training). Subjects will return to the clinic weekly during the at-home phase for a single session of retraining and progression, and participate in periodic retesting. * All training and testing will be performed uniformly across all subjects in both groups. Multiple assessment metrics will capture data at the beginning and end of the 2-week in-lab CN-NINM intervention period and at 3-week intervals. After completion of the formal training period, subjects will stop using the device (withdrawal stage) and will be tested every 3 weeks over an additional 12 weeks to monitor and assess changes due to withdrawal of the PoNS. This will yield a total of 10 data points for each subject. * If successful, this study would indicate that CN-NINM may improve rehabilitation outcomes and reduce time required to improve function.

Interventions

DEVICEBalance and Gait Training using neurostimulation modulation.

CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.

DEVICESham Device

The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* All candidates will have a balance disorder as a result of a traumatic brain injury (TBI). * All candidates will have a NeuroCom® Sensory Organization Test (SOT) composite score at least 8 points below normal after adjustment for age and height \[based on normative data\]. * All candidates will be between the ages of 18 and 65 (at the time of screening). * If female of childbearing potential, the candidate agrees to use adequate contraception throughout participation in the study (from enrollment to completion). * All candidates must have access to a treadmill. * All candidates will be at least 1 year post-injury. * All candidates will have a neuroradiologic scan and report after their most recent TBI. * All candidates will be ambulatory and able to walk for 20 minutes. * All candidates, if on medications, will not have had any major changes in type or dosage within 3 months of enrollment. * All candidates will have participated in a focused physical rehabilitation program for their TBI and feel that they have reached a plateau. * All candidates will be able to understand and willing to give informed consent.

Exclusion criteria

* All candidates that have oral health problems (e.g. gum disease, active cankers, piercings, oral surgery within the previous 3 months). * All candidates with non-removable metal orthodontic devices (e.g., braces) or oral cavity piercings that could interfere with PoNS™ use. * All candidates who have chronic infectious diseases (e.g. hepatitis, HIV, TB). * All candidates with unmanaged hypertension. * All candidates with unmanaged diabetes, or complications due to diabetes (e.g. retinopathy, neuropathy, renal disease). * All candidates with neurological disorders other than those attributed to their primary diagnosis (e.g., MS, PD, ALS, AD or other dementia, uncontrolled pain). * All candidates with a history of oral cancer. * All candidates who have been treated for any type of cancer other than basal cell carcinoma within the past year. * All candidates who have had a penetrating injury, craniotomy (with the exception of a burr hole \[trephination\] for resolution of acute subdural hematoma), or refractory subdural hematoma. * Exceptions for other abnormalities identified in neuroradiologic scan reports that are asymptomatic and not expected to change may be made on a case by case basis by the Medical Advisor. * All candidates with chronic use of psychoactive or psychostimulant medications that, in the opinion of the investigators, would compromise the subject's ability to comprehend and perform the study activities. * All candidates who have a pacemaker, or are identified as at-risk for cardiovascular events. * All candidates who are pregnant or lactating. * All candidates with a lower extremity biomechanical prosthetic. * All candidates with a history of seizures (except those in the acute or post-acute phases, and are controlled). * All candidates who who experienced a loss of consciousness greater than 24 hours as a result of their TBI. * All candidates with a severe score in any of the Attention, Memory, or Executive Functions categories on the Cognitive Linguistic Quick Test (CLQT). * All candidates who, in the opinion of the investigators, are unable to feel the stimulation and successfully complete the device level setting procedure.

Design outcomes

Primary

MeasureTime frameDescription
NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Baseline, 2, 14, and 26 weeksSOT assesses the ability to use visual, proprioceptive, and vestibular cues to maintain postural stability. Subjects stand on dual-force plates and the anterior-posterior sway is recorded. 6 conditions are tested (3, 20-sec trials each): Eyes open on firm surface; Eyes closed on firm surface; Eyes open with sway referenced visual surround; Eyes open on sway referenced support surface; Eyes closed on sway referenced support surface; Eyes open on sway referenced support surface and surround. A composite score is generated by the NeuroCom BalanceMaster System using an algorithm to calculate the composite score from each of the 3 serial repetitions for each of the 6 conditions (a total of 18 sub-scores). The calculated composite score ranges from 0 to 100 points; 0 is complete failure, 100 is perfect stability, 70 is the lower limit normal. Group mean score for each time-point is reported.

Other

MeasureTime frameDescription
Change in 6-Minute Walk Test (6MWT) Over BaselineChange from Baseline at 2,14, and 26 weeksMeasures walking speed over ground. The six-minute walk test (6MWT) measures the distance in meters an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Change in 6MWT over baseline for each time point is reported.
Change in Dynamic Gait Index (DGI) Over BaselineChange from Baseline at 2,14, and 26 weeksAssesses walking, walking with head turns, over and around obstacles, and stairs. Dynamic Gait Index - A semiquantitative tool used to evaluate a patient's ability to modify gait by changing task demands, esp. in patients with dizziness and balance deficits. This test is used to identify patients, esp. older adults, who are predisposed to falling. Participants are graded from 0 (low function) to 3 (high function) on 8 tasks: normal walking, their ability to vary walking speed, turn their heads, turn their bodies, step over and around obstacles, climb stairs, turn while walking. The range of scores is 0-24, higher scores indicate higher function, with a score of 24 considered Normal. Change from baseline to 2, 14, and 26 weeks is reported.
Change in California Verbal Learning Test (CVLT) Over BaselineChange from Baseline at 2,14, and 26 weeksAssesses short- and long-term verbal memory by evaluating a series of recall and recognition tasks. The test is scored via computer algorithm. A score of 50 represents is equal to the population mean, the normal range is between 40-60 (ie. +/- 1 SD from the mean). The total range of possible scores is 0 (no recalled words) to 100 (all correct). Change in score over baseline at 2, 14, and 26 weeks is reported.
Change in Brief Symptom Inventory 18 (BSI 18) Over BaselineChange from Baseline at 2,14, and 26 weeksA short, reliable, 18-question instrument for assessment of psychological distress (anxiety, depression, & somatization) in a clinical population. It is scored from 0-4, with a total range of possible scores 0-72 where higher scores indicate more distress.
Change in Neurobehavioral Symptom Inventory Over BaselineChange from Baseline at 2,14, and 26 weeksA 22-item subjective inventory of TBI symptoms where symptoms are scored on a scale of 0 (none) to 4 (very severe). Lower scores indicate decreased symptoms. Group mean change from baseline at 2, 14, and 26 weeks is reported. The range of possible scores if from 0 to 88. The results are reported as a change from baseline.
Change in Pittsburgh Sleep Quality Index (PSQI) From BaselineBaseline at 2,14, and 26 weeksSubjective inventory of sleep habits, duration and quality. It is scored from 7 components (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction) to provide a global PSQI score. Most items are scored from 0-3 where 3 is a negative extreme, therefore lower cumulative scores are indicative of improved sleep habits. The total range of scores is from 0-21.
Change in Headache Disability Index (HDI) From BaselineChange from Baseline at 2,14, and 26 weeksAssesses frequency & severity of headaches via a 25-item questionnaire where an answer of 'yes' = 4 points, 'sometimes' = 2 points, and 'no' = 0 points. The lower the score, the less frequent and severe the symptoms. The range of possible scores is 0 to 100. The results are reported as a change from baseline.
Electromyography (EMG)Change from Baseline at 2,14, and 26 weeksMeasures muscle activation patterns during gait.
Computerized Video Nystagmography (VNG)Change from Baseline at 2,14, and 26 weeksMeasures eye movement control under 3 static (x and y axis fixation, spontaneous nystagmus), and 3 dynamic conditions (random saccade, smooth pursuit, optokinetic nystagmus).
Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineChange from Baseline at 2,14, and 26 weeksAssesses visual spatial abilities. The Symbol Search and Coding WAIS-IV subtests measure Processing Speed, an indicator of the rate of cognitive processing and creating an appropriate response output. The tasks require attending to visual material, visual scanning and perception, spatial organization, hand-eye coordination, and paired associative learning. The raw score (processing speed for each test) is converted to a scaled score 1-10 for each and summed for a total possible score of 2-20, the higher the score, the more improved the processing speed. Change in score from baseline to 2, 14, and 26 weeks are reported.

Countries

United States

Participant flow

Pre-assignment details

13 subjects provided consent but did not enroll in the study at sites under UW-Madison purview.

Participants by arm

ArmCount
Neurostimulation
Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
22
Control (Non-zero, Minimally Perceivable Stimulation)
Balance and gait training using non-zero, minimally perceivable stimulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
21
Total43

Baseline characteristics

CharacteristicControl (Non-zero, Minimally Perceivable Stimulation)TotalNeurostimulation
Age, Continuous53.24 years
STANDARD_DEVIATION 10.55
53.89 years
STANDARD_DEVIATION 9.14
54.05 years
STANDARD_DEVIATION 5.91
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants40 Participants20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants3 Participants2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants2 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
20 Participants39 Participants19 Participants
Sex: Female, Male
Female
14 Participants28 Participants14 Participants
Sex: Female, Male
Male
7 Participants15 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 21
other
Total, other adverse events
11 / 228 / 21
serious
Total, serious adverse events
3 / 221 / 21

Outcome results

Primary

NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)

SOT assesses the ability to use visual, proprioceptive, and vestibular cues to maintain postural stability. Subjects stand on dual-force plates and the anterior-posterior sway is recorded. 6 conditions are tested (3, 20-sec trials each): Eyes open on firm surface; Eyes closed on firm surface; Eyes open with sway referenced visual surround; Eyes open on sway referenced support surface; Eyes closed on sway referenced support surface; Eyes open on sway referenced support surface and surround. A composite score is generated by the NeuroCom BalanceMaster System using an algorithm to calculate the composite score from each of the 3 serial repetitions for each of the 6 conditions (a total of 18 sub-scores). The calculated composite score ranges from 0 to 100 points; 0 is complete failure, 100 is perfect stability, 70 is the lower limit normal. Group mean score for each time-point is reported.

Time frame: Baseline, 2, 14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationNeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 1470.89 score on a scaleStandard Deviation 11.45
NeurostimulationNeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Baseline42.77 score on a scaleStandard Deviation 17.54
NeurostimulationNeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 2674.83 score on a scaleStandard Deviation 11.86
NeurostimulationNeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 263.73 score on a scaleStandard Deviation 15.06
Control (Non-zero, Minimally Perceivable Stimulation)NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 2671.50 score on a scaleStandard Deviation 17.5
Control (Non-zero, Minimally Perceivable Stimulation)NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Baseline36.24 score on a scaleStandard Deviation 16.09
Control (Non-zero, Minimally Perceivable Stimulation)NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 1471.21 score on a scaleStandard Deviation 16.95
Control (Non-zero, Minimally Perceivable Stimulation)NeuroCom Computerized Dynamic Posturography Sensory Organization Test (SOT)Week 262.00 score on a scaleStandard Deviation 22.32
Comparison: P-Value for Sensory Organization Test results at 2 weeksp-value: 0.41t-test, 2 sided
Comparison: P-Value for Sensory Organization Test results at 14 weeksp-value: 0.47t-test, 2 sided
Comparison: P-Value for Sensory Organization Test results at 26 weeksp-value: 0.99t-test, 2 sided
Other Pre-specified

Change in 6-Minute Walk Test (6MWT) Over Baseline

Measures walking speed over ground. The six-minute walk test (6MWT) measures the distance in meters an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. Change in 6MWT over baseline for each time point is reported.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in 6-Minute Walk Test (6MWT) Over BaselineWeek 233.06 metersStandard Deviation 75.01
NeurostimulationChange in 6-Minute Walk Test (6MWT) Over BaselineWeek 1472.27 metersStandard Deviation 79.97
NeurostimulationChange in 6-Minute Walk Test (6MWT) Over BaselineWeek 2676.81 metersStandard Deviation 95.41
Control (Non-zero, Minimally Perceivable Stimulation)Change in 6-Minute Walk Test (6MWT) Over BaselineWeek 219.02 metersStandard Deviation 39.41
Control (Non-zero, Minimally Perceivable Stimulation)Change in 6-Minute Walk Test (6MWT) Over BaselineWeek 1462.30 metersStandard Deviation 51.04
Control (Non-zero, Minimally Perceivable Stimulation)Change in 6-Minute Walk Test (6MWT) Over BaselineWeek 2674.38 metersStandard Deviation 49.21
Other Pre-specified

Change in Brief Symptom Inventory 18 (BSI 18) Over Baseline

A short, reliable, 18-question instrument for assessment of psychological distress (anxiety, depression, & somatization) in a clinical population. It is scored from 0-4, with a total range of possible scores 0-72 where higher scores indicate more distress.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 2-5.32 units on a scaleStandard Deviation 9.1
NeurostimulationChange in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 14-4.16 units on a scaleStandard Deviation 9.41
NeurostimulationChange in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 26-7.72 units on a scaleStandard Deviation 10.15
Control (Non-zero, Minimally Perceivable Stimulation)Change in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 2-2.38 units on a scaleStandard Deviation 7.53
Control (Non-zero, Minimally Perceivable Stimulation)Change in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 14-2.95 units on a scaleStandard Deviation 6.13
Control (Non-zero, Minimally Perceivable Stimulation)Change in Brief Symptom Inventory 18 (BSI 18) Over BaselineWeek 26-2.50 units on a scaleStandard Deviation 6.93
Other Pre-specified

Change in California Verbal Learning Test (CVLT) Over Baseline

Assesses short- and long-term verbal memory by evaluating a series of recall and recognition tasks. The test is scored via computer algorithm. A score of 50 represents is equal to the population mean, the normal range is between 40-60 (ie. +/- 1 SD from the mean). The total range of possible scores is 0 (no recalled words) to 100 (all correct). Change in score over baseline at 2, 14, and 26 weeks is reported.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in California Verbal Learning Test (CVLT) Over BaselineWeek 28.95 units on a scaleStandard Deviation 8.48
NeurostimulationChange in California Verbal Learning Test (CVLT) Over BaselineWeek 149.00 units on a scaleStandard Deviation 11.34
NeurostimulationChange in California Verbal Learning Test (CVLT) Over BaselineWeek 2610.28 units on a scaleStandard Deviation 11.79
Control (Non-zero, Minimally Perceivable Stimulation)Change in California Verbal Learning Test (CVLT) Over BaselineWeek 29.71 units on a scaleStandard Deviation 6.63
Control (Non-zero, Minimally Perceivable Stimulation)Change in California Verbal Learning Test (CVLT) Over BaselineWeek 1411.30 units on a scaleStandard Deviation 9.4
Control (Non-zero, Minimally Perceivable Stimulation)Change in California Verbal Learning Test (CVLT) Over BaselineWeek 2611.00 units on a scaleStandard Deviation 9.7
Other Pre-specified

Change in Dynamic Gait Index (DGI) Over Baseline

Assesses walking, walking with head turns, over and around obstacles, and stairs. Dynamic Gait Index - A semiquantitative tool used to evaluate a patient's ability to modify gait by changing task demands, esp. in patients with dizziness and balance deficits. This test is used to identify patients, esp. older adults, who are predisposed to falling. Participants are graded from 0 (low function) to 3 (high function) on 8 tasks: normal walking, their ability to vary walking speed, turn their heads, turn their bodies, step over and around obstacles, climb stairs, turn while walking. The range of scores is 0-24, higher scores indicate higher function, with a score of 24 considered Normal. Change from baseline to 2, 14, and 26 weeks is reported.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Dynamic Gait Index (DGI) Over BaselineWeek 22.23 score on a scaleStandard Deviation 2.88
NeurostimulationChange in Dynamic Gait Index (DGI) Over BaselineWeek 143.58 score on a scaleStandard Deviation 3.53
NeurostimulationChange in Dynamic Gait Index (DGI) Over BaselineWeek 264.12 score on a scaleStandard Deviation 3.67
Control (Non-zero, Minimally Perceivable Stimulation)Change in Dynamic Gait Index (DGI) Over BaselineWeek 143.42 score on a scaleStandard Deviation 3.11
Control (Non-zero, Minimally Perceivable Stimulation)Change in Dynamic Gait Index (DGI) Over BaselineWeek 21.76 score on a scaleStandard Deviation 2.72
Control (Non-zero, Minimally Perceivable Stimulation)Change in Dynamic Gait Index (DGI) Over BaselineWeek 263.45 score on a scaleStandard Deviation 3.41
Other Pre-specified

Change in Headache Disability Index (HDI) From Baseline

Assesses frequency & severity of headaches via a 25-item questionnaire where an answer of 'yes' = 4 points, 'sometimes' = 2 points, and 'no' = 0 points. The lower the score, the less frequent and severe the symptoms. The range of possible scores is 0 to 100. The results are reported as a change from baseline.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Headache Disability Index (HDI) From BaselineWeek 2-16.00 score on a scaleStandard Deviation 23.56
NeurostimulationChange in Headache Disability Index (HDI) From BaselineWeek 14-9.79 score on a scaleStandard Deviation 18.02
NeurostimulationChange in Headache Disability Index (HDI) From BaselineWeek 26-14.78 score on a scaleStandard Deviation 21.17
Control (Non-zero, Minimally Perceivable Stimulation)Change in Headache Disability Index (HDI) From BaselineWeek 2-4.38 score on a scaleStandard Deviation 20.15
Control (Non-zero, Minimally Perceivable Stimulation)Change in Headache Disability Index (HDI) From BaselineWeek 14-11.00 score on a scaleStandard Deviation 20.62
Control (Non-zero, Minimally Perceivable Stimulation)Change in Headache Disability Index (HDI) From BaselineWeek 26-13.60 score on a scaleStandard Deviation 23.48
Other Pre-specified

Change in Neurobehavioral Symptom Inventory Over Baseline

A 22-item subjective inventory of TBI symptoms where symptoms are scored on a scale of 0 (none) to 4 (very severe). Lower scores indicate decreased symptoms. Group mean change from baseline at 2, 14, and 26 weeks is reported. The range of possible scores if from 0 to 88. The results are reported as a change from baseline.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Neurobehavioral Symptom Inventory Over BaselineWeek 2-13.52 score on a scaleStandard Deviation 9.17
NeurostimulationChange in Neurobehavioral Symptom Inventory Over BaselineWeek 14-10.47 score on a scaleStandard Deviation 10.12
NeurostimulationChange in Neurobehavioral Symptom Inventory Over BaselineWeek 26-9.94 score on a scaleStandard Deviation 15.49
Control (Non-zero, Minimally Perceivable Stimulation)Change in Neurobehavioral Symptom Inventory Over BaselineWeek 2-7.52 score on a scaleStandard Deviation 13.58
Control (Non-zero, Minimally Perceivable Stimulation)Change in Neurobehavioral Symptom Inventory Over BaselineWeek 14-7.10 score on a scaleStandard Deviation 9.83
Control (Non-zero, Minimally Perceivable Stimulation)Change in Neurobehavioral Symptom Inventory Over BaselineWeek 26-8.40 score on a scaleStandard Deviation 10.46
Other Pre-specified

Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline

Subjective inventory of sleep habits, duration and quality. It is scored from 7 components (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction) to provide a global PSQI score. Most items are scored from 0-3 where 3 is a negative extreme, therefore lower cumulative scores are indicative of improved sleep habits. The total range of scores is from 0-21.

Time frame: Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Pittsburgh Sleep Quality Index (PSQI) From BaselineBaseline9.318 score on a scaleStandard Deviation 4.874
NeurostimulationChange in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 28.682 score on a scaleStandard Deviation 5.213
NeurostimulationChange in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 148.611 score on a scaleStandard Deviation 4.742
NeurostimulationChange in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 268.294 score on a scaleStandard Deviation 5.084
Control (Non-zero, Minimally Perceivable Stimulation)Change in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 268.238 score on a scaleStandard Deviation 5.272
Control (Non-zero, Minimally Perceivable Stimulation)Change in Pittsburgh Sleep Quality Index (PSQI) From BaselineBaseline9.182 score on a scaleStandard Deviation 4.934
Control (Non-zero, Minimally Perceivable Stimulation)Change in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 148.714 score on a scaleStandard Deviation 5.349
Control (Non-zero, Minimally Perceivable Stimulation)Change in Pittsburgh Sleep Quality Index (PSQI) From BaselineWeek 27.810 score on a scaleStandard Deviation 5.698
Other Pre-specified

Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over Baseline

Assesses visual spatial abilities. The Symbol Search and Coding WAIS-IV subtests measure Processing Speed, an indicator of the rate of cognitive processing and creating an appropriate response output. The tasks require attending to visual material, visual scanning and perception, spatial organization, hand-eye coordination, and paired associative learning. The raw score (processing speed for each test) is converted to a scaled score 1-10 for each and summed for a total possible score of 2-20, the higher the score, the more improved the processing speed. Change in score from baseline to 2, 14, and 26 weeks are reported.

Time frame: Change from Baseline at 2,14, and 26 weeks

ArmMeasureGroupValue (MEAN)Dispersion
NeurostimulationChange in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 20.95 score on a scaleStandard Deviation 2.38
NeurostimulationChange in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 141.11 score on a scaleStandard Deviation 2.9
NeurostimulationChange in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 261.78 score on a scaleStandard Deviation 2.44
Control (Non-zero, Minimally Perceivable Stimulation)Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 21.14 score on a scaleStandard Deviation 2.29
Control (Non-zero, Minimally Perceivable Stimulation)Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 141.25 score on a scaleStandard Deviation 2.02
Control (Non-zero, Minimally Perceivable Stimulation)Change in Wechsler Adult Intelligence Scale - Symbol Search and Coding (WAIS-IV) Over BaselineWeek 261.20 score on a scaleStandard Deviation 2.35
Other Pre-specified

Computerized Video Nystagmography (VNG)

Measures eye movement control under 3 static (x and y axis fixation, spontaneous nystagmus), and 3 dynamic conditions (random saccade, smooth pursuit, optokinetic nystagmus).

Time frame: Change from Baseline at 2,14, and 26 weeks

Other Pre-specified

Electromyography (EMG)

Measures muscle activation patterns during gait.

Time frame: Change from Baseline at 2,14, and 26 weeks

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026